CN116940340A - 纤维肌痛的环苯扎林治疗 - Google Patents

纤维肌痛的环苯扎林治疗 Download PDF

Info

Publication number
CN116940340A
CN116940340A CN202180089897.8A CN202180089897A CN116940340A CN 116940340 A CN116940340 A CN 116940340A CN 202180089897 A CN202180089897 A CN 202180089897A CN 116940340 A CN116940340 A CN 116940340A
Authority
CN
China
Prior art keywords
cyclobenzaprine hcl
mannitol
eutectic
cyclobenzaprine
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180089897.8A
Other languages
English (en)
Chinese (zh)
Inventor
S·莱德尔曼
G·M·沙利文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tongnix Pharmaceutical Holding Co
Original Assignee
Tongnix Pharmaceutical Holding Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tongnix Pharmaceutical Holding Co filed Critical Tongnix Pharmaceutical Holding Co
Publication of CN116940340A publication Critical patent/CN116940340A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202180089897.8A 2020-12-07 2021-12-07 纤维肌痛的环苯扎林治疗 Pending CN116940340A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063122469P 2020-12-07 2020-12-07
US63/122,469 2020-12-07
PCT/US2021/062244 WO2022125572A1 (en) 2020-12-07 2021-12-07 Cyclobenzaprine treatment for fibromyalgia

Publications (1)

Publication Number Publication Date
CN116940340A true CN116940340A (zh) 2023-10-24

Family

ID=79686930

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180089897.8A Pending CN116940340A (zh) 2020-12-07 2021-12-07 纤维肌痛的环苯扎林治疗

Country Status (9)

Country Link
US (2) US20240024256A1 (https=)
EP (1) EP4255407A1 (https=)
JP (1) JP2023554692A (https=)
CN (1) CN116940340A (https=)
AU (1) AU2021396509A1 (https=)
CA (1) CA3204202A1 (https=)
IL (1) IL303497A (https=)
MX (1) MX2023006720A (https=)
WO (1) WO2022125572A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3260042A1 (en) * 2022-06-21 2023-12-28 Tonix Pharmaceuticals Holding Corp. CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF A (SARS)-COV-2 (PASC) INFECTION
WO2025137348A1 (en) * 2023-12-19 2025-06-26 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine hcl for use in treating fibromyalgia with early onset response and favorable tolerability and side effect profile

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107072968A (zh) * 2014-09-18 2017-08-18 通尼克斯制药控股有限公司 环苯扎林盐酸盐的低共熔混合物配制剂
WO2020039256A1 (en) * 2018-08-20 2020-02-27 Tonix Pharma Holdings Limited Methods of treating acute stress disorder and posttraumatic stress disorder

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63822B1 (sr) 2012-06-15 2023-01-31 Tonix Pharma Holdings Ltd Kompozicije i postupci za transmukoznu apsorpciju
SMT202400324T1 (it) 2013-03-15 2024-11-15 Tonix Pharma Ltd Formulazioni eutettiche di ciclobenzaprina cloridrato e mannitolo

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107072968A (zh) * 2014-09-18 2017-08-18 通尼克斯制药控股有限公司 环苯扎林盐酸盐的低共熔混合物配制剂
WO2020039256A1 (en) * 2018-08-20 2020-02-27 Tonix Pharma Holdings Limited Methods of treating acute stress disorder and posttraumatic stress disorder

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia (RELIEF)", Retrieved from the Internet <URL:https://clinicaltrials.gov/study/NCT04172831?term=NCT04172831&rank=1&tab=history&a=11#version-content-panel> *
GREGORY SULLIVAN等: "A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia (FM): Evidence for a Broad Spectrum of Activity on the FM Syndrome", 《AMERICAN COLLEGE OF RHEUMATOLOGY》, vol. 71, no. 10, 1 October 2019 (2019-10-01), pages 1, XP009534074 *
S SANTANDREA等: "A Double-Blind Crossover Study of Two Cyclobenzaprine Regimens in Primary Fibromyalgia Syndrome", 《JOURNAL OF INTERNATIONAL MEDICAL RESEARCH》, vol. 21, 1 March 1993 (1993-03-01), pages 74 - 80, XP000956189 *

Also Published As

Publication number Publication date
AU2021396509A1 (en) 2023-06-29
WO2022125572A1 (en) 2022-06-16
EP4255407A1 (en) 2023-10-11
US20240024256A1 (en) 2024-01-25
JP2023554692A (ja) 2023-12-28
CA3204202A1 (en) 2022-06-16
MX2023006720A (es) 2023-08-18
IL303497A (en) 2023-08-01
US20260108477A1 (en) 2026-04-23
AU2021396509A9 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
US20260108477A1 (en) Cyclobenzaprine treatment for fibromyalgia
US20250268889A1 (en) Compounds and combinations thereof for treating neurological and psychiatric conditions
KR101184138B1 (ko) 일반적인 선형 발포성 경구 펜타닐 투약 제형 및 투여 방법
Hulisz Efficacy of zinc against common cold viruses: an overview
NEIDHART et al. Comparative trial of the antiemetic effects of THC and haloperidol
EP3576738B1 (en) Gaboxadol monohydrate in the treatment of tinnitus
CN111479592A (zh) 阿片样物质使用障碍、阿片样物质戒断症状和慢性疼痛的治疗
TW202019400A (zh) 治療急性壓力症候群及創傷後壓力症候群之方法
WO2019157273A1 (en) Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere&#39;s disease, tourette&#39;s syndrome, attention deficit hyperactivity disorder and addiction
AU2002363874B2 (en) Use of desoxypeganine for treating clinical depression
HK40102591A (zh) 纤维肌痛的环苯紮林治疗
CN120379655A (zh) (sars)-cov-2感染的急性后后遗症(pasc)的环苯扎林治疗
Schachtel et al. (420) Demonstration of the safety and efficacy of CL-108 for moderate-to-severe pain with reduction of opioid-induced nausea and vomiting
LAMOTRIGINE INTERACTION WITH OTHER DRUGS
US20250322926A1 (en) Early onset response, favorable tolerability, and side effect profile in the treatment of fibromyalgia
Bhat et al. Evaluation of propranolol, flunarizine and divalproex sodium in prophylaxis of migraine
Silver et al. Clinical experience with transdermal nicotine patch in Tourette syndrome
US20250025461A1 (en) Treatment of severe and uncomplicated malaria
Minhas et al. Post-herpetic neuralgia in elderly: can topical capsaicin 8% patch be considered as first-line therapy?
WO2020061404A1 (en) Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions
US10864192B2 (en) Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions
US20080090874A1 (en) Treatment of breakthrough pain in patients suffering from chronic low back pain
Mystakidou et al. Pain and symptom management. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics.
US20230404955A1 (en) Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere’s disease, tourette’s syndrome, attention deficit hyperactivity disorder and addiction
Gogineni et al. Tobacco Dependence Treatment: Pharmacist’s Role

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40102591

Country of ref document: HK